AlphaRose Therapeutics

We imagine a different world for children born with severe autism, epilepsy, or neurodevelopmental delays. Our technology has shown to fix the underlying cause of these types of genetic diseases, and often reverse damage done by genetic mutations that cause these terrible outcomes. Children talking for the first time, no more seizures, swimming when they could barely walk. This is why AlphaRose exists.

AlphaRose finished an oversubscribed round with notable commitments from Labcorp and Suncoast Ventures. With over $5M raised, AlphaRose is now raising a $15M round to take Rosiphersen into clinical trials and validate their RINAE platform by getting human data.

Highlights:

• Rosiphersen shows a 10x safety window in vivo ($700M in potential peak annual revenue)
• RINAE AI platform showed best in class performance, with a 70% target hit rate
• SOT Caller epigenetic platform is showing positive data in human cells for upregulation
• Robust pipeline of similar neuro genetic treatments ($2.5B in potential peak annual revenue)

AlphaRose is poised to turn a 240B market, into over $1T with platform approval from regulators.

A quick update:

It's been nonstop at AlphaRose! We just came back from JPM with some significant investor conversations, and heading to Saudi Arabia at the end of Jan for more. Our valuation is rising, and our team is growing! We have a $3M CLN open that should close soon, with $2.1M already filled. We're open to investors that want to make an impact in patients lives with genetic medicine, changing the way that we think about how we make and deploy the medicine of the future for patients.

• We acquired RareLabs, a personalized genetic medicine lab here in Austin, Tx with an achievable goal of $1.2M in revenue in 2026. We've created 8 new treatments in the lab, which two patients are already on and seeing results.
• We're in multiple conversations with institutions for AlphaRose to acquire clinical stage assets for our Rare HoldCo model. (these most likely will yield a 200-600% return at peak AR, currently only available to our company investors)

AlphaRose has built significant value over this last quarter, with 5B+ in potential revenue waiting to be unlocked. Our team is very excited about the incredible opportunities in front of us.

To that end, we are announcing a $2m Convertible Note that just opened, Oct 1st - Nov 30th for select investors. The note is filling fast. Please reach out to me immediately if you have interest. ([email protected] / 512.940.4164)

Some significant markers:

• We are currently now advancing 5 genetic treatments in the pipeline. ($XB in potential annual revenue)
• We are continuing to develop our two proprietary RNA technologies (abcDNA and SOT Caller) poised for large licensing deals as early as 2026. (see Merck and Skyhawk as an example)
• We are in multiple discussions with potential partners in biotech, venture, and healthcare systems.
• We closed our Reg CF Round Sept 30th with $1.6M in additional investment.
• We have two non-dilutive grants we're working on totaling over $50M in potential capital.